2nd liver transplant linked to good outcomes in PSC
A second liver transplant results in transplant and patient outcomes in people with primary sclerosing cholangitis (PSC) that are comparable or better than those…
Cholangitis
Antibiotic may ease IBD related to primary sclerosing cholangitis
Four weeks of treatment with vancomycin, a common antibiotic, lowered inflammatory bowel disease (IBD) in people with primary sclerosing cholangitis (PSC), data from a…
Poor primary biliary cholangitis outcomes tied to two antibodies
Testing positive for the self-reactive anti-gp210 and anti-centromeric antibodies significantly increases the risk of poor liver-related outcomes for people with primary biliary cholangitis (PBC),…
Three-factor tool may predict response to UDCA in PBC: Study
A predictive tool that incorporates several blood biomarkers may help to identify primary biliary cholangitis (PBC) patients who are less likely to respond to treatment…
Livdelzi approved in UK as PBC treatment for certain adults
Gilead Sciences’ Livdelzi (seladelpar) has been approved in the U.K. as a treatment for adults with primary biliary cholangitis (PBC), either in combination…
Cour’s CNP-104 granted FDA orphan drug status for treating PBC
The U.S. Food and Drug Administration (FDA) has granted orphan drug status to CNP-104, Cour Pharmaceuticals’ treatment candidate for primary biliary cholangitis (PBC).
Liver donor type may sway primary sclerosing cholangitis outcomes
Liver transplants from a living donor may mean a lower success and a higher need for a second transplant relative to those from a deceased…
Committee recommends seladelpar approval in EU for treating PBC
A branch of the European Medicines Agency (EMA) has recommended that Gilead Sciences’ oral therapy seladelpar be approved in the European Union as a…
Sleep disorders common in PBC, linked to severe disease: Study
Sleep disorders affect about half of adults with primary biliary cholangitis (PBC), and are associated with more severe disease and worse outcomes, according to…
PBC therapy Ocaliva pulled from EU market with court decision
Ocaliva (obeticholic acid) is no longer available to treat primary biliary cholangitis (PBC) across the European Union (EU), with an earlier decision…
Recent Posts
- Patient identification guidelines may help diagnose biliary atresia earlier
- Hepatitis B gene-editing therapy PBGENE-HBV shows early promise
- 2nd liver transplant linked to good outcomes in PSC
- AI models may aid intrahepatic cholestasis of pregnancy prediction
- With so many specialists, scheduling appointments can be tricky